CD8A and non-small cell lung carcinoma: Previous studies [25, 26] reported that CIK/DC-CIK therapy could significantly increase the proportion of CD3+ T cells, CD3+ CD4+ T cells, and the ratio of CD4+/CD8+ T cells and improve the tumor responses for NSCLC.